Treatment of advanced ovarian cancer

European Journal of Cancer

Volumn 37, Issue SUPPL. 9, 2001, Pages

  Du Bois, A ^a  

^a Dr Horst Schmidt Klinken   (Germany)

Author keywords

Chemotherapy; Ovarian cancer; Platinum

Indexed keywords

ALKYLATING AGENT; ALTRETAMINE; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; PACLITAXEL; TOPOTECAN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LIPOSOMES; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; TOPOTECAN;

EID: 0035669576     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)80331-2     Document Type: Editorial

References (44)

1. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma
2. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study
3. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma
4. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian cancer
5. Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer
6. Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide inpatients with advanced epithelial ovarian cancer
7. Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer
8. Cyclophosphamide, doxorubicin, and cisplatin chemotherapy for ovarian carcinoma: A meta-analysis
9. Impact of doxorubicin on survival in advanced ovarian cancer
10. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma
11. Comparison of the emetogenic potential between cisplatin and carboplatin
12. Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer
13. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III study randomized trial in stages III and IV ovarian cancer
14. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group
15. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
16. Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: A randomized trial in stage III-IV epithelial ovarian carcinoma
17. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: A comparison of equally myelosuppressive regimens
18. Chemotherapy in advanced ovarian cancer: An overview of randomized clinical trials
19. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma
20. Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma
21. Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study
22. Extended phase II study of paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
23. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
24. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer
25. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIIB, IIC, III, IV comparing paclitaxel-cisplatin and paclitaxel-carboplatin
26. Cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line chemotherapy in ovarian cancer: Interim analysis of an AGO Study Group trial
27. Paclitaxel-cisplatin vs. paclitaxel-carboplatin in previously untreated ovarian cancer
28. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial
29. Randomized phase III study of cisplatin (CIS)/ paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
30. Phase III Randomized Study of Cisplatin versus Paclitaxel versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
31. A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 patients randomised into 3rd International Collaborative Ovarian Neoplasm Study (ICON 3)
32. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
33. Final analysis of a phase III, randomized study of topotecan (T) vs. paclitaxel (P) in advanced epithelial ovarian cancer (OC): International Topotecan Study Group
34. Topotecan, an active drug in second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
35. Topotecan versus paclitaxel for the treatment of advanced epithelial ovarian cancer
36. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel
37. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
38. Gemcitabine in cisplatin-resistant ovarian cancer
39. Ovarian cancer: New insights into systemic therapy
40. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
41. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation
42. Interim analysis of a phase III randomised trial of Doxil/Caelyx versus topotecan in the treatment of patients with relapsed ovarian cancer
43. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study
44. Oral etoposide is active against platinum-resistant epithelial ovarian cancer